Northwestern University-led Phase 3 trials reported that retatrutide significantly reduced knee pain in two studies enrolling more than 1,000 participants with obesity and painful knee osteoarthritis. The company highlighted substantial benefit at the highest dose studied, tying weight-loss pharmacology to patient-reported musculoskeletal outcomes. The data extend the clinical narrative for retatrutide beyond glycemic and weight effects, potentially broadening positioning in musculoskeletal indications where pain and function endpoints can be decisive for adoption. As obesity and osteoarthritis therapies increasingly compete on tolerability and breadth of outcomes, regulators and payers will likely focus on safety signals, effect consistency by dose, and the magnitude of pain relief relative to existing standards of care.